Evolent Health (EVH) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 21.6% year-over-year to $621.4 million, driven by new contracts and Performance Suite, but offset by a $41.8 million true-down and higher medical costs, especially in oncology.

• Adjusted EBITDA was $31.8 million, down from $48.7 million in Q3 2023, significantly impacted by $42 million in higher-than-expected medical costs, mainly from oncology and new claims data.

• Net loss attributable to common shareholders was $31.2 million, an improvement from $33.2 million loss in Q3 2023, with a net loss margin of (5.0)%.

• Six record new revenue agreements were signed in Q3, expected to add $200 million in annualized revenue, including a major oncology deal with a top-five national payer.

• Management is taking aggressive actions to improve profitability, including seeking $100 million in annualized rate increases, auditing claims, managing costs, and considering shifting loss-making risk contracts to fee-based models.

Financial highlights

• Q3 2024 revenue: $621.4 million (up 21.6% YoY); Adjusted EBITDA: $31.8 million (margin 5.1%, down from 9.5% YoY); net loss: $31.2 million.

• Annual Adjusted EBITDA guidance revised to $160–$175 million; Q4 guidance set at $22–$37 million.

• Annual revenue guidance updated to $2.55–$2.575 billion; Q4 revenue expected at $642–$667 million.

• Cash and cash equivalents stood at $96.6 million as of September 30, 2024; cash from operations was $18.7 million in Q3.

• Adjusted income attributable to common shareholders was $4.7 million, or $0.04 per share, compared to $20.0 million, or $0.18 per share, in Q3 2023.

Outlook and guidance

• 2024 Adjusted EBITDA guidance lowered due to persistent elevated medical costs; no incremental rate increases assumed until January 2025.

• Long-term targets reaffirmed: average annual revenue growth above 15% and Adjusted EBITDA growth of 20%, though off a lower base.

• No longer expects to exit 2024 at a $300 million Adjusted EBITDA run rate; update to be provided with Q4 results.

• Management expects continued pressure from high medical cost inflation, especially in specialty pharmacy and oncology.

• The company believes current liquidity is sufficient for at least the next twelve months.